Literature DB >> 30094258

Management of ruptured liver segment IV hepatocellular carcinoma: is transarterial embolization (TAE) superior to chemoembolization (TACE)?-the jury is still out.

Anargyros Bakopoulos1, Nikolaos Koliakos1, Diamantis I Tsilimigras1, Dimitrios Schizas1, Demetrios Moris2, Argiris Angelopoulos3, Spyridon Spanakos3, Eleftherios Spartalis4, Pavlos Patapis1, Panagiotis Skandalakis3, Theodoros Troupis3.   

Abstract

HCC rupture is a potentially life-threatening complication owing to underlying vascular dysfunction and coagulopathy. There is still a debate in the literature concerning the best approach in patients presenting in the emergency setting with shock due to spontaneous HCC rupture. In the current report, we describe the case of a 66-year-old female patient with ruptured HCC who was treated successfully by emergency transarterial embolization (TAE) with complete response proved by gradual shrinkage of the tumor. This impressive complete response suggests that TAE followed by elective hepatectomy could be an efficient approach for patients with Child-Pugh class A liver function and adequate liver remnant. More studies are needed in order to construct specific guidelines for the treatment of rHCC that will be based on the disease severity and the patient status.

Entities:  

Keywords:  Transarterial embolization (TAE); hepatocellular carcinoma (HCC); rupture

Year:  2018        PMID: 30094258      PMCID: PMC6064791          DOI: 10.21037/atm.2018.06.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  12 in total

Review 1.  Spontaneous ruptured hepatocellular carcinoma.

Authors:  Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Eiji Uchida
Journal:  Hepatol Res       Date:  2015-03-02       Impact factor: 4.288

Review 2.  Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review.

Authors:  Demetrios Moris; Jeffery Chakedis; Steven H Sun; Gaya Spolverato; Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Eleftherios Spartalis; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2017-11-08       Impact factor: 3.454

3.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Authors:  Al B Benson; Michael I D'Angelica; Daniel E Abbott; Thomas A Abrams; Steven R Alberts; Daniel Anaya Saenz; Chandrakanth Are; Daniel B Brown; Daniel T Chang; Anne M Covey; William Hawkins; Renuka Iyer; Rojymon Jacob; Andrea Karachristos; R Kate Kelley; Robin Kim; Manisha Palta; James O Park; Vaibhav Sahai; Tracey Schefter; Carl Schmidt; Jason K Sicklick; Gagandeep Singh; Davendra Sohal; Stacey Stein; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Andrew X Zhu; Karin G Hoffmann; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

Review 4.  Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.

Authors:  Roberto S Oliveri; Jørn Wetterslev; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 5.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 6.  Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

Authors:  Laura Marelli; Rosa Stigliano; Christos Triantos; Marco Senzolo; Evangelos Cholongitas; Neil Davies; Jonathan Tibballs; Tim Meyer; David W Patch; Andrew K Burroughs
Journal:  Cardiovasc Intervent Radiol       Date:  2007 Jan-Feb       Impact factor: 2.740

7.  Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up.

Authors:  Guido Bonomo; Vittorio Pedicini; Lorenzo Monfardini; Paolo Della Vigna; Dario Poretti; Gianluigi Orgera; Franco Orsi
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-03       Impact factor: 2.740

Review 8.  Comparison of hepatocellular carcinoma in Eastern versus Western populations.

Authors:  Su Pin Choo; Wan Ling Tan; Brian K P Goh; Wai Meng Tai; Andrew X Zhu
Journal:  Cancer       Date:  2016-09-13       Impact factor: 6.860

9.  Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.

Authors:  Karen T Brown; Richard K Do; Mithat Gonen; Anne M Covey; George I Getrajdman; Constantinos T Sofocleous; William R Jarnagin; Michael I D'Angelica; Peter J Allen; Joseph P Erinjeri; Lynn A Brody; Gerald P O'Neill; Kristian N Johnson; Alessandra R Garcia; Christopher Beattie; Binsheng Zhao; Stephen B Solomon; Lawrence H Schwartz; Ronald DeMatteo; Ghassan K Abou-Alfa
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

10.  Treatment outcomes of spontaneous rupture of hepatocellular carcinoma with hemorrhagic shock: a multicenter study.

Authors:  Feng Zhong; Xin-Sheng Cheng; Kun He; Shi-Bo Sun; Jie Zhou; Hai-Ming Chen
Journal:  Springerplus       Date:  2016-07-16
View more
  2 in total

1.  Case report: Urgent liver pathologies: All in one.

Authors:  Goran Pavlek; Ivan Romic; Kristina Juzbasic; Ana Marija Alduk; Igor Petrovic; Rudolf Radojkovic; Dario Grbavac; Hrvoje Silovski
Journal:  Front Surg       Date:  2022-07-20

Review 2.  Ruptured Hepatocellular Carcinoma: What Do Interventional Radiologists Need to Know?

Authors:  Jingxin Yan; Ting Li; Manjun Deng; Haining Fan
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.